Cipla Stock

Cipla Equity

The The Equity of Cipla (CIPLA.NS) as of Aug 16, 2026 is 311.93 B INR. In the previous year, The Equity was 267.06 B INR — a change of 16.80% (higher).

Equity

311.93 BINR

YoY

16.80%

Last updated:

In 2026, Cipla's equity was 311.93 B INR, a 16.80% increase from the 267.06 B INR equity in the previous year.

Access this data via the Eulerpool API

Cipla Stock analysis

What does Cipla do? Cipla Ltd is an Indian pharmaceutical company based in Mumbai. The company was founded in 1935 and is now one of the largest producers of generics worldwide. The name "Cipla" is an abbreviation for "Chemical, Industrial & Pharmaceutical Laboratories". Business Model: Cipla specializes in the production of high-quality generics. This means that they manufacture medication that has the same active ingredients as the original drugs. This allows them to offer medication at a significantly lower price. However, Cipla not only offers generics but also develops its own innovative medication. The focus is on therapy areas such as oncology, respiratory diseases, HIV/AIDS, diabetes, and cardiovascular diseases. Divisions: Cipla is divided into several divisions, including generics, specialty drugs, and biologics. The generics division is the company's core competence. Here, Cipla produces a variety of medications in different forms, such as tablets, capsules, suspensions, etc. The specialty drugs division focuses on innovative medications that are usually more expensive than generics. This includes medications for the treatment of cancer or autoimmune diseases. In the biologics division, Cipla produces biotechnology products based on the use of living cells. Products: Cipla offers a wide range of products, including medications for asthma, diabetes, hypertension, and infectious diseases. Some of the most well-known medications are Escitalopram (an antidepressant), Seroflo (an asthma medication), Tenofovir (an HIV medication), and Sorafenib (a cancer medication). The company continuously works on new products and invests heavily in research and development. Cipla also has a social responsibility. The company is involved in the fight against HIV/AIDS and produces life-saving medication for this disease at an affordable price. Furthermore, Cipla has launched a program called "Cipla Foundation" which works towards improving healthcare in developing countries. Overall, Cipla has achieved impressive growth and is now one of the most significant pharmaceutical companies worldwide. The company has proven that it is possible to offer high-quality medication at an affordable price and still be successful. Cipla is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Cipla's Equity

Cipla's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Cipla's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Cipla's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Cipla's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Cipla’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Cipla stock

The Equity of Cipla is 311.93 B INR in 2026.

The Equity of Cipla changed from 267.06 B INR to 311.93 B INR, representing a 16.80% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Cipla since 2006 – with annual values, charts, and detailed analysis.

The Equity's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Cipla historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Cipla

All Key Metrics — Cipla